A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Sponsor: Eli Lilly and Company
Listed as NCT05051579, this PHASE2 trial focuses on Obesity and Overweight and Obesity and remains completed. Sponsored by Eli Lilly and Company, it has been updated 15 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Oct 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 10 earlier versions
-
Nov 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .